title: CFTR potentiators: not an open and shut case.
abstract: Insights into the positive and negative effects of drugs to treat cystic fibrosis (CF) patients with a common mutation raise questions about how we discover and translate CF therapeutics (Veit et al. and Cholon et al., this issue).
authors.affiliation: Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, OH 45229, USA.
authors.forename: John P
authors.initials: JP
authors.lastname: Clancy
mesh_terms: D000627:Aminophenols / Q000494:pharmacology / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000188:drug therapy; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009154:Mutation / Q000235:genetics; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000627:Aminophenols; D015363:Quinolones; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor